Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Anthony E. Yeo"'
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Gout is a heterogeneous inflammatory disease with numerous clinical manifestations. A composite means to assess the impact of therapy on numerous aspects of gout could be useful. Methods Results from patients treated with peglotic
Externí odkaz:
https://doaj.org/article/f756290d57da4f7ca0cf4076c36e5216
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Pegloticase is a recombinant mammalian uricase conjugated to polyethylene glycol approved in the United States for treatment of chronic refractory gout. It can profoundly decrease serum urate to
Externí odkaz:
https://doaj.org/article/fede54bbd26f495c8aeb1429a4f51cb2
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-7 (2017)
Abstract Background To assess frequency and distribution of infusion reactions (IRs) in responders and nonresponders in randomized clinical trials (RCTs) of intravenous pegloticase and the utility of the National Institute of Allergy and Infectious D
Externí odkaz:
https://doaj.org/article/12fbbd89ed2c4e2bb37c4cd8fbfc0dee
Publikováno v:
Clinical and Experimental Rheumatology. 39:1085-1092
To determine factors associated with gout flares in subjects treated with pegloticase.Gout flares from two randomised controlled trials comparing pegloticase (8 mg every 2 weeks [q2] or monthly [q4]) versus placebo were analysed. Responders had persi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1a804ef4db5296ec85a183a0b8f174
https://doi.org/10.55563/clinexprheumatol/b7jjnb
https://doi.org/10.55563/clinexprheumatol/b7jjnb
Publikováno v:
Clinical and Experimental Rheumatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e2d88823925569acc5f69857b493e5e
https://doi.org/10.55563/clinexprheumatol/1138gr
https://doi.org/10.55563/clinexprheumatol/1138gr
Publikováno v:
Acr Open Rheumatology
Objective The objective of this study is to assess criteria for gout remission and to use the results to inform criteria for a complete response (CR). Methods A post hoc analysis of two clinical trials was undertaken to determine the frequency with w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3f8299d4d253e18d730c69d9294c39
https://doi.org/10.1002/acr2.1025
https://doi.org/10.1002/acr2.1025
Publikováno v:
American Journal of Gastroenterology. 117:e1030-e1030
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::432c8b345cb9963620fd1f26e7e1a1f1
https://doi.org/10.14309/01.ajg.0000862384.69672.c4
https://doi.org/10.14309/01.ajg.0000862384.69672.c4
Publikováno v:
Clinical and Experimental Rheumatology.
To assess the benefit of long-term urate-lowering with pegloticase.The results from two, 6-month, randomised controlled trials (RCTs) and their 30-month open-label extension (OLE) were analysed. Efficacy was assessed in urate responders (patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdbc7dcc0588093956aa7123b1c072ef
https://doi.org/10.55563/clinexprheumatol/3m095f
https://doi.org/10.55563/clinexprheumatol/3m095f
Autor:
Prathyusha Bachali, Amrie C. Grammer, Nicholas S. Geraci, Anthony E. Yeo, Michelle Petri, Michelle D. Catalina, Peter E. Lipsky
Publikováno v:
JCI Insight
Gene expression signatures can stratify patients with heterogeneous diseases, such as systemic lupus erythematosus (SLE), yet understanding the contributions of ancestral background to this heterogeneity is not well understood. We hypothesized that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a679a25a69a64f1c69d671fd891f429
https://doi.org/10.1101/2020.05.31.20114660
https://doi.org/10.1101/2020.05.31.20114660
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Background Gout is a heterogeneous inflammatory disease with numerous clinical manifestations. A composite means to assess the impact of therapy on numerous aspects of gout could be useful. Methods Results from patients treated with pegloticase or pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19827ae98098d822890d824fa358e245
http://europepmc.org/articles/PMC7325077
http://europepmc.org/articles/PMC7325077